Skip to content
Storytelling Co – Lifestyle
Author:
Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
November 12, 2026
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
November 10, 2026
Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
November 5, 2026
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
October 22, 2026
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
September 30, 2026
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
September 10, 2026
Verrica Pharmaceuticals to Present at H.C. Wainwright Conference
September 8, 2026
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
August 27, 2026
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 6, 2026
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
August 6, 2026
1
2
Next Page
→